Combined Data Show Superiority of LAMA/LABA in COPD
medscape.com
Patients with chronic obstructive pulmonary disease (COPD) experienced significantly fewer acute exacerbations when a long-acting muscarinic antagonist (LAMA) was added to a long-acting beta agonist (LABA) than when an inhaled corticosteroid (ICS) was added.